SAFETY AND EFFECTIVENESS OF TRI VALENT INACTIVATED SPLIT VIRION INFLUENZA VACCINE IN PATIENTS WITH RHEUMATOID DISORD ERS

SAFETY AND EFFECTIVENESS OF TRI VALENT INACTIVATED SPLIT VIRION INFLUENZA VACCINE IN PATIENTS WITH RHEUMATOID DISORD ERS

Objective: to evaluate the safety and effectiveness of vaccination with trivalent split virion influenza vaccine in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS), estimate the effect of vaccination on rheumatoid disorder (RD) activity and influenza and influenzalike illness...

Full description

Saved in:

Bibliographic Details
Main Authors:	D. V. Bukhanova, В. S. Belov, G. M. Tarasova, Sh. F. Erdes, T. V. Dubinina, G. V. Lukina, M. V. Cherkasova, M. E. Diatroptov
Format:	Article
Language:	Russian
Published:	ABV-press 2018-07-01
Series:	Klinicist
Subjects:	rheumatoid arthritis ankylosing spondylitis autoimmune diseases rheumatoid disorders comorbid infections comorbidity influenza vaccination influenza vaccine trivalent split virion influenza vaccine
Online Access:	https://klinitsist.abvpress.ru/Klin/article/view/337
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Immunogenicity, Effectiveness, and Safety of Trivalent Inactivated Influenza Split Vaccine in Patients with Inflammatory Joint Diseases Receiving Modern Antirheumatic Therapy
by: M. M. Baranova, et al.
Published: (2024-06-01)

Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the 2022/23 influenza season
by: Marina Amaral de Avila Machado, et al.
Published: (2024-12-01)

The averted costs due to influenza vaccination with trivalent and quadrivalent vaccines
by: S. M. Kharit, et al.
Published: (2017-06-01)

Immunogenicity, efficacy and safety of the three-valent inactivated influenza split vaccine in patients with ankylosing spondylitis and psoriatic arthritis
by: M. M. Baranova, et al.
Published: (2024-06-01)

Vaccination In Rheumatology: Present And Future
by: B. S. Belov, et al.
Published: (2020-05-01)

Disparities in Seasonal Influenza Vaccination in Europe
by: Katinka M. Giezeman‐Smits, et al.
Published: (2025-07-01)

Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children
by: Adib Rodriguez Solares, et al.
Published: (2014-09-01)

IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS OF A TWO-YEAR FOLLOW-UP STUDY
by: M. S. Naumtseva, et al.
Published: (2017-01-01)

VACCINATION IN RHEUMATIC DISEASES: AN ALLY OR AN ENEMY?
by: B. S. Belov
Published: (2018-09-01)

The Use of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients with Rheumatoid Arthritis
by: M. S. Naumtseva, et al.
Published: (2015-08-01)

EFFICACY AND SAFETY OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: M. S. Naumtseva, et al.
Published: (2015-05-01)

Immunogenicity and efficiency of a 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results of a 5-year follow up study
by: D. V. Bukhanova, et al.
Published: (2018-12-01)

VACCINATION IN RHEUMATOLOGY: CURRENT ASPECTS
by: B. S. Belov, et al.
Published: (2014-12-01)

IMMUNOGENICITY AND SAFETY OF A TRIVALENT SUBUNIT IMMUNOADJUVANT INFLUENZA VACCINE IN CHILDREN WITH TYPE 1 DIABETES: RESULTS OF A PROSPECTIVE COMPARATIVE STUDY
by: Аlla A. Tarasova, et al.
Published: (2016-11-01)

Results of Clinical Trials of the First Russian 4-valent Flu Vaccine
by: D. A. Lioznov
Published: (2018-09-01)

ASSESSMENT OF THE IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH RHEUMATIC DISEASES
by: M. S. Naumtseva, et al.
Published: (2016-02-01)

About influenza and flu vaccination: opinion the students’ medical school V.V. Balzhieva, L.A. Khlebnik
by: V. V. Balzhieva, et al.
Published: (2025-06-01)

Which Srategy will stop Flu
by: O. V. Shamsheva
Published: (2016-11-01)

Early and Late Influenza Vaccine Effectiveness in South Korea During the 2023–2024 Season
by: Yu Jung Choi, et al.
Published: (2025-02-01)

Enhanced passive safety surveillance of standard-dose and high-dose influenza vaccines in Finland and Germany 2023–24 season
by: Marina Amaral de Avila Machado, et al.
Published: (2025-12-01)

Real-world effectiveness of live attenuated influenza vaccines (LAIV) and inactivated influenza vaccines (IIV) in children from 2003 to 2023: a systematic literature review and network meta-analysis
by: Anke L. Stuurman, et al.
Published: (2025-12-01)

VACCINATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS AND PROSPECTS
by: B. S. Belov, et al.
Published: (2018-07-01)

Cell-Cultured Influenza Vaccine Enhances IFN-γ+ T Cell and Memory T Cell Responses Following A/Victoria/2570/2019 IVR-215 (A/H1N1) Infection
by: Kyu-Ri Kang, et al.
Published: (2024-12-01)

Seasonal influenza vaccines: Variability of immune responses to B lineage viruses
by: Matthew S. Miller, et al.
Published: (2024-12-01)

Comparative Analysis of Approaches to Assess the Quality of Inactivated Influenza Vaccines: Regulatory Requirements in the Russian Federation and European Union
by: L. M. Khantimirova, et al.
Published: (2021-01-01)

Safety and Influenza Infections in Children Aged 6–35 Months Receiving Cell Culture-Derived Inactivated Quadrivalent Influenza Vaccine During the 2023–2024 Influenza Season in South Korea
by: Hye Eun Lee, et al.
Published: (2025-05-01)

SAFETY ASSESSMENT OF TWO SUBUNIT INFLUENZA VACCINES IN CHILDREN WITH A BURDENED ALLERGOANAMNEZ
by: M. G. Galitskaya, et al.
Published: (2015-08-01)

A preliminary exploration of influenza-like illness surveillance and influenza vaccination in Jing’an District of Shanghai， 2017‒2023
by: HUA Ruijue, et al.
Published: (2025-04-01)

Evaluation of Seasonal Inactivated Influenza Vaccines Prophylactic Efficacy
by: K. V. Zhdanov, et al.
Published: (2022-11-01)

The Study in Animal Models of Local Action, Acute and Chronic Toxicity of Inactivated Influenza Vaccine Ultriks in Syringe
by: O. G. Kurskaya, et al.
Published: (2015-06-01)

Protective Impact of Influenza Vaccination on Healthcare Workers
by: Yimei Tian, et al.
Published: (2024-10-01)

Influenza, pneumococcal, and COVID-19 vaccination coverage and hesitancy in adults with psychiatric disorders
by: Vasfiye Demir Pervane, et al.
Published: (2025-04-01)

A Bayesian re-analysis of the DANFLU-1 trial
by: Daniel Modin, et al.
Published: (2025-12-01)

Results of a clinical study of the influenza tetravalent inactivated subunit adjuvant vaccine Grippol Quadrivalent in children aged 6 months to 5 years (inclusive)
by: Viktor V. Romanenko, et al.
Published: (2024-07-01)

Comparative effectiveness of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children over multiple influenza seasons (2019–2023)
by: Allyn Bandell, et al.
Published: (2025-08-01)

Coverage of influenza vaccination and influencing factors among healthcare workers in Shandong Province, China, 2021–2022
by: Yuwei Liu, et al.
Published: (2024-12-01)

Influence of perceived influenza-like symptoms on intention to receive seasonal influenza vaccination
by: Renske Eilers, et al.
Published: (2025-03-01)

Evaluating Families’ Opinions of Routine Influenza Vaccination in Children Under 5 Years of Age in Spain
by: Sílvia Burgaya-Subirana, et al.
Published: (2025-01-01)

POTENTIAL OF THE RUSSIAN FEDERATION IN EXPORTS OF ANTI-INFLUENZA VACCINES IN LATIN AMERICAN COUNTRIES
by: V. P. Trukhin, et al.
Published: (2019-01-01)

Seasonal influenza vaccination: Overcoming immunosenescence with enhanced vaccines
by: Wendy Boivin, et al.
Published: (2025-06-01)